

6. Literaturverzeichnis

- Anasagasti MJ, Olasso E, Calvo F, et al.- Interleukin 1-dependent and-independent mouse melanoma metastases. J Natl Cancer Inst 1997;89;645–651
- Apte R., Voronov E.-Interleukin-1-a major pleiotropic cytokine in tumor-host interactions-Cancer Biology 2002;12;277-290
- Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland-3. erweiterte, aktualisierte Auflage, Saarbrücken 2002
- Arend W.P., Guthridge C.-Biological role of interleukin 1 receptor antagonist isoforms-Ann Rheum Dis 2000;59(suppl I);160-164
- Arend W.P., Malyak M. et al.-INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in biology-Ann Rev Immunol 1998;16;27-55
- Arend W.P.-The balance between IL-1 and IL-1 Ra in disease-Cytokine Growth Faktors Reviews 2002;13;323-340
- Bauknecht Th.-Neue therapeutische Ansätze inclusive Genterapie-Onkologe 1998;4;1159-1167
- Bast RCT, Klug TL, St John E et al.-A randomioimmunoassay using a monoclonal antibody to monitor the course of ovarian cancer. N Engl J Med 1983;309:883-7
- Benedetti-Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Mancini N, Scambia G et al.-Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer; a randomized clinical trial. J Natl Cancer Inst 2005;97;560-566
- Bidwell JL, Keen L, Gallagher G et al.-Cytokine gene polymorphim in human disease: on-line databases-Genes and Immunity 1999;1;3-19
- Boyd J., Rubin SC.- Hereditary ovarian cancer: Molecular genetics and clinical implications (Review)-Gynecol Oncol 1997; 64;196-206
- Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ-Comparison of Standard and CA-125 Response Criteria in

- Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel. *J Clin Oncol* 1999;17;501-508
- Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ- Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol* 2002;20;1248-1259
 - Brun JL, Bouzigon E et al.-Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases-*Gynecol Obstet Fertil* 2000;28(3);223-231
 - Burger R., Grosen EA. et al.-Host-Tumor interaction in ovarian cancer: Spontaneous Release of Tumor Necrosis Factor and Interleukin-1 Inhibitors by Purified Cell Populations from Human Ovarian Carcinoma in vitro-*Gynecologic Oncology* 1994;55;294-303
 - Burghardt E, Girardi F, Lahousen M-Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. *Gynecol Oncol* 1991 ;40;103-106
 - Burke F., Relf M. et al.-A Cytokine Profile of Normal and Malignant Ovary-Cytokine 1996;8(7);578-585
 - Cancer-Facts & Figures 2000
 - Casagrande JT, Pike MC, Ross RK et al. "Incessant ovulation" and ovarian cancer. *Lancet* 1979; 2;170
 - Castrilli G, Tatone A-IL-1alfa promote growth of neoplastic human cervical cells *Br. J Cancer* 1997;75(6):855-859
 - Chen Z., Fadiel A., Feng Y. et al.-Ovarian Epithelial Carcinoma Tyrosine Phosphorilation, cell proliferation and Ezrin Translocation Are Stimulated by Interleukin 1 α and Epidermal Growth Factor-*Cancer* 2001; 92(12);3068-3074
 - Chi DS, Liao JB, Leon LF et al.-Identification of prognostic factors in advanced epithelial ovarian carcinoma. *Gynecol Oncol* 2001;82:532-537
 - Colotta F., Dower S. et al.-The type II 'decoy' receptor: a novel regulatory pathway for interleukin-1-*Immunol Today* 1994;15;562-566

- Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE-Preoperative CA125levels: an independent prognostic factor for epithelial ovarian cancer. *Obstet Gynecol* 2002;100:59-64
- Cox DR-Regressions models and life-tables-*JR Stat Soc* 1972;34;187-220
- Cramer DW et al.-Dietary animal fat in relation to ovarian cancer risk. *Obstet Gynecol* 1984;63;883
- Cramer DW et al.-Factors affecting the association of oral contraceptives and ovarian cancer. *N Engl J Med* 1982; 307;1047
- Cramer DW et al.-Mumps, menarche, menopause and ovarian cancer. *Am J Obstet Gynecol* 1983;147;1
- Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB.Scottish Gynaecological Cancer Trial Group. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. *Proc Am Soc Clin Oncol* 2005; #5003 Abstract
- Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial. *Journal of Clinical Oncology*, Vol 23, No 34 (December 1), 2005: pp. 8802-8811
- Cytokine Bulletin-New IL-1 Family Member Elicits antitumor Immunity; May 2003
- Danis VA, Millington M, Hyland VJ, Grennan D.-Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. *Clin Exp Immunol* 1995; 99: 303–310
- Dekker SK, Vink J, Bruijn, JA, et al.- Characterization of interleukin-1 a-induced melanoma cell motility: inhibition by type 1 and type 2 receptor-blocking monoclonal antibodies. *Melanoma Res* 1997;7;223–230

- Dembo AJ, Davy M, Stenwig AE, Berle EJ, Busch RS, Kjorstad K- Prognostic factors in patients with stage I epithelial ovarian cancer. *Ostet Gynecol* 1990;75;263-273
- Deutsche Krebsgesellschaft-Maligne Ovarialtumoren. Kurzgefasste Interdisziplinäre Leitlinien 2004. Diagnostik und Therapie maligner Erkrankungen. 4. Auflage München. Bern. Wien. New York
- Di Giovine FS., Takhs E., Blakemore AI. et al.-Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1beta)- *Hum Mol Genet* 1992;1;450
- Dinarello CA, Bunn PA-Fever. *Semin Oncol* 1997;24:288-297
- Dinarello CA-Biologic basis for interleukin-1 in disease-*Blood* 1996;87;2095-2147
- Dinarello CA-Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist-*Int Rev Immunol* 1998;16;457-499
- Dinarello CA-The interleukin-1 family:10 years of discovery;*FASEB J* 1994;8;1314-1325
- Di Re F, Baiocchi G, Fontanelli R, Gross G et al.-Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastasis. *Gynecol Oncol* 1996 Sep;62(3):360-5
- Du Y., Dodel RC., Eastwood BJ. et al.-Association of an interleukin-1 alpha gene polymorphism with Alzheimer's disease-*Neurology* 2000;55;480-483
- Du Bois A, Pfisterer J, Kellerman L, Kreienberg R- Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? Ergebnisse einer Umfrage der ORGANKOMMISSION OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) *Geburtsh Frauenheilk* 2001; 61: 863-871
- Eisenkop SM, Friedman RL, Wang HJ-Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. *Gynecol Oncol* 1998;69;103-108

- Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer. *Gynecol Oncol* 2002;87;260-267
- El-Omar EM, Rabkin C., et al.-Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms-*Gastroenterology* 2003;124;1193-1201
- El-Omar EM, Carrington M., et al.-Interleukin-1 polymorphism associated with increased risk of gastric cancer-*Nature* 2000;404;398-402
- Enomoto T, Kuragaki C, Yamasaki M, Sugita N-Is Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary Sensitive to Combination Chemotherapy with Paclitaxel and Carboplatin? 39th ASCO Annual Meeting 2003;Abstract 1797
- Fathalla MF-Incessant ovulation-a factor in ovarian neoplasia?-*Lancet* 1971;2(7716);163
- Fujiwaki R., Hata T., Miyazaki K. et al.-Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers-*British Journal of Obstetrics and Gynaecology* 1997;104;1407-1408
- Fujiwaki R., Iida K., Nakayama K. et al.-Clinical significance of interleukin-1 receptor antagonist in patients with cervical cancer-*Gynecologic Oncology* 2003;89;77-83
- Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE.-Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. *J Reprod Med* 1996;41:140-142
- Gomolka M., Menninger H. et al.-Immunoprinting:various genes are associated with increased risk to develop rheumatoid arthritis in different groups of adults patients-*J Mol Med* 1995;73;19-29
- Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel *Journal of Clinical Oncology*, Vol 24, No 4 (February 1), 2006:579-586

- Grossi M., Quinn MA et al.-Ovarian cancer:patterns of care in Victoria during 1993-1995-Medical Journal Australia 2002;177;11-16
- Hall SK., Perregaux DG., Gabel A. et al.-Correlation of Polymorphic Variation in the Promoter Region of the Interleukin-1 β Gene With Secretion of Interleukin-1 β Protein-Arthritis & Rheumatism 2004; 50(6);1976-1983
- Harter P, Breitbach GP, Tanner B, Sehouli J, Heilmann V, Lueck HJ, Kuhn W, Wimberger P, Ortmann O, du Bois A.-Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Proc Am Soc Clin Oncol 2005;#5004 Abstract
- Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J-Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial; Annals of Surgical Oncology 2006
- Haukim N., Bidwell JL, Smith AJP et al.-Cytokine gene polymorphism in human disease:on-line databases, Supplement 2-Genes and Immunity 2002;3;313-330
- Hefler Lukas A., Ludwig Elisabeth et al-Polymorphism of the Interleukin-1 Gene Cluster and Ovarian Cancer-J Soc Gynecol Investig 2002;9;386-90
- Heintz APM, Hacker NF, Lagasse LD-Epidemiology and etiology of ovarian cancer: A review-Obstetrics and Gynecology 1985;Vol. 66
- Henderson BE, Pike MC, Ross RK et al. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42; 3232
- Hess V, A'Hern RP, Gore ME-Relative Platinum Resistance of mucinous Carcinoma of the Ovary.39th ASCO Annual Meeting 2003;Abstract 1796
- Hulkkonen J, Laippala P, Hurne M.-A rare allele combination of interleukin gene complex is associated with high interleukin-1plasma levels in healthy individuals. Eur Cytokine Netw 2000; 11: 251–255

- Huleihel M., Maymon E. et al.-Distinct patterns of expression of interleukin-1 α and β by normal and cancerous human ovarian tissues-*Eur. Cytokine Netw.* 1997;8(2);179-187
- Hurme M, Santtila S.-IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1genes. *Eur J Immunol* 1998; 28: 2598–2602
- Ikeda K., Sakai K., Yamamoto R. et al.-Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MRD-1 and p53 in stages II-IV ovarian cancer-*Int J Gynecol Cancer* 2003;776-784
- Jacobs IJ, van Nagell J. R., DePriest Jr. P. D. Screening for Epithelial Ovarian Cancer; *Ovarian Cancer: Controversies in Management*; Hrsg.: David M. Gershenson, William P. McGuire, Medical Division of Pearson Professional Limited 1998;1-15
- Jacobs IJ, Menon U-Progress challenges in screening for early detection of ovarian cancer. *Mol Cell Proteomics* 2004;3;355-366
- Kabir S., Grant C., Daar A.S.-Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric carcinoma. *Cancer Letters* 1995;95;207-212
- Kaplan, E.L. and Meier, P.-Nonparametric estimation from incomplete observations, *J. Am. Stat. Assoc.* 1958;4;57-81
- Kilian PL., Kaffka KL., Biondi DA et al.-Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR 3)-*Cancer Res* 1991;51;1823-1828
- Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP-Human kallikrein 8, a novel biomarker for ovarian carcinoma. *Cancer Res* 2003;63;2771-2774
- Kondera-Anasz Z., Mielczarek-Palacz A., Switala J.-Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer-*Ginekol Pol.* 2003;74(9);761-766
- Krebs HB, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A.-Role of Ca 125 as tumor marker in ovarian carcinoma. *Obstet.Gynecol.* 1986;67:473-477

- Kvale G, Heuch I, Nilssen S et al.-Reproductive factors and risk of ovarian cancer: A prospective study. *Int J Cancer* 1989; 42;246
- Landis SH, Murray T, Bolden S-Cancer Statistic-CA *Cancer J Clin* 1999;8;49-54
- Ledermann JA on behalf of ICON and AGO Collaborators; Medical Research Council (MRC) Clinical Trials Unit, London, UK. Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4 / OVAR 2.2). *Proc Amer Soc Clin Oncol* 2003;22 abstract #1794
- Ledermann JA, Wheeler S- How Should We Manage Patients with “Platinum-Sensitive” Recurrent Ovarian Cancer? *Cancer Investigation* Volume 22, Supplement 2 / 2004 ;2 - 10
- Lichtenegger W, Sehouli J. State of the Art-multimodale Therapie des Ovarialkarzinoms *Gyn* 2003;(8):277-280
- Liu S., Liu JH, Huang H. et al.-Analysis of risk factors for epithelial ovarian cancer recurrence-*Ai Zheng* 2003 Nov.;22(11);197-200
- Lynch HT et al.- Familial ovarian carcinoma-*Am J Med* 1986;81;1073
- Lynch HT et al.- Hereditary carcinoma of the ovary and associated cancers: A study of two families. *Gynecol Oncol* 1990;36; 48
- Luesley D, Lawton F, Blackledge G et al.-Failure of second look laparotomy to influence survival in epithelial ovarian cancer.*Lancet* 1988;10;599-603
- MJ Webb-Surgery in gynecologic oncology-Yesterday, Today and Tomorrow-Zentralblatt Gynäkologie 2002;124;454-460
- Machado JC, Pharoah P., Sousa S. et. al.-Interleukin 1B and Interleukin 1 RN Polymorphisms are associated with increased risk of gastric carcinoma-*Gastroenterology* 2001;121;823-829
- Makar A, Baekelandt M, Tropè CO, Kristensen GB.-The prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian Cancer. *Gynecol Oncology* 1995 Feb;56(2):175-180

- Markmann M- Pre-maintenance CA-125 level predicts risk of ovarian cancer relapse. A Report March 20th2006; Journal of Clinical Oncology.
- Mateo R, Singh G, Jabbour N, Palmer S et al.-Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors. Gynecol Oncol 2005;97;266-270
- Mayr D, Diebold J-Grading of ovarian carcinomas.Int J Gynecol Pathol 2000;19;348-353
- McGuire WP, Hoslins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M.-Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334;1-6
- Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeverajah AR, Skates SJ et. al.-Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.Br J Obstet Gynecol 2000;107;165-169
- Mora M., Carinci V. et al-Differential expression of the human IL-1 alpha and beta genes-Prog Clin Biol Res 1990;349;205
- Moradi MM., Carson L., Weinberg B. et al.-Serum and ascitic fluid levels of Interleukin-1, Interleukin-6 and Tumor Necrosis Factor-Alpha in Patients with Ovarian Epithelial Cancer-Cancer 1993;72(8);2433-2440
- Mustea A., Sehouli J., Könsgen D. et al.-Interleukin 1 Receptor Antagonist (IL-1RA) Polymorphism in Women with Cervical Cancer-Anticancer Research 2003;23;1099-1102
- Nahhas WA.Ovarian cancer-Current outlook on this deadly disease-Postgraduate medicine 1997;Vol 102,No 3
- Nashan D., Luger T.A.-Interleukin-1-Grundlagen und Pathophysiologie-Haut 1999;50;680-688
- Nicklin MJ., Weith A. et al.-A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta and interleukin-1 receptor antagonist genes-Genomics 1994;19;382-384

- NIH.National Institutes of Health Consensus Development Conference Statement.Ovarian Cancer: Screening, Treatment and Follow-up.Gynecol Oncol 1994;55;4-12
- Nordfors et al.-Pyrosequencing-2002 Summen Mut 19(4): 395-401
- Nyrén P., Karamohamed S., Ronaghi M.-Detection of single-base changes using a bioluminometric primer extension assay-Anal Biochem 1997;244:367-73
- Nyrén P., Petterson B., Uhlén M.-Solid phase DNA minisequencing by an Enzymatic luminometric inorganic pyrophosphate detection assay-Analytical Biochemistry 1993;208;171-175
- Oelmann E., Kraemer A., Serve H. et al.-Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1-Int. J. Cancer 1997;71;1066-1076
- Pantschenko AG., Pushar I et al.-The interleukin-1 family of cytokines and receptors in human breast cancer:implications for tumor-Int J Oncol 2003 Aug;23(2);269-284
- Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ.-Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:888-893
- Pecorelli S, Odicino F, Maisonneuve P et al.-Carcinoma of the ovary-J Epidemiol Biostatistics 1998;3;75-102
- Pecorelli S. et al.-FIGO Annual Report on the Results of Treatment in Gynecologic Cancer. FIGO Committee on Gynecologic Oncology-Journal of Epidemiology and Biostatistics 2001;24
- Pfisterer J, Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002 Jun;29(3 Suppl 12):22-7
- Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hammann M, Hasenburg A et al.-The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(3);195-8

- Pfisterer J, Plante M, Vergote I, du Bois A, Eisenhauer E, for the AGO-OVAR, NCIC CTG&EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. *Int J Gynecol Cancer* 2005;15 (Suppl 1):36-41
- Pociot F., Molvig J. et al.- A TaqI polymorphism in the human interleukin-1 β (IL-1 β) gene correlates with IL-1 β secretion in vitro-Eur. *J. Clin. Invest.* 1992;22;396-402
- Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H-The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer.*Gynecol Oncol* 1996; 61;109-112
- Punnonen J., Heinonen PK. et al.-Production of interleukin-1 β and tumor necrosis factor- α in patients with benign or malignant ovarian tumors-*J Cancer Res Clin Oncol* 1991;117; 587-592
- Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. *J Clin Ultrasound* 1997;25:217-225
- Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K. Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. 38th ASCO Annual Meeting 2002;Abstract 801
- Salzer H., Denison U. et al.-Das Ovarialkarzinom-ACO Manual
- Santilla S, Hurme M.-IL-1 receptor antagonist(IL-1 Ra) plasma levels are co-ordinately regulated by both IL-1 Ra and IL-1 β genes-Eur. *J. Immunol.* 1998;28;2598-2602
- Santilla S., Savinainen K., Hurme M. -Presence of IL-1 RA allele 2 is associated with enhanced IL-1 β production in vitro-*Scand J Immunol* 1998;47;195-8
- Schelling M, de Waal JC. Präoperative Diagnostik, Diagnosesicherung. In Kuhn: *Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge*“, Tumorzentrum München 2001;14-15

- Scheuermann W., Rensing K., Schmidt H. et al.-Mortalität an bösartigen Brust- und Genitaltumoren bei Frauen in Bundesrepublik Deutschland von 1970-1994-Geburtsh. U. Frauenheilk. 1997;423-428
- Schildkraut JM, Halabi S, Bastos E et al.-Prognostic factors in Early-Onset Epithelial Ovarian Cancer:A Populational-Based Study-Obstet Gynecol 2000;95;119-127
- Schmalfeldt B, du Bois A, Burges A et al.- Diagnostik und Therapie maligner Ovarialtumoren 2005:Die Empfehlung der Kommission Ovar der AGO. Zentralbl Gynakol 2006;128:11-17
- Schmidt-Matthiesen H, Bastert G, Wallwiener D.: Gynäkologische Onkologie. 6. Auflage Stuttgart, New York: Schattauer-Verlag, 2000
- Sehouli J, Stengel D, Hindenburg, Camara O, Porzsolt F, Lichtenegger W.-Herausforderung Evidence-based Medicine: Sinn und Unsinn diagnostischer Tests in der Gynäkologie. Zentralblatt für Gynäkologie 2001;123:127-131
- Sehouli J., Akdogan Z., Heinze T., Könsgen D., Stengel D., Mustea A., Lichtenegger W.-Preoperative Determination of CASA (Cancer Associated Serum Antigen) and CA125 for the Discrimination between Benign and Malignant Pelvic Tumor Mass: A Prospective Study.Anticancer Res 2003;23;1115-1118
- Sehouli J., Könsgen D., A. Mustea et al.-„IMO“-Intraoperatives Mapping des Ovarialkarzinom-Zentralblatt Gynäkologie 2003;125;129-135
- Sehouli J., Könsgen D., Nimpsch R. et al.-Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies-Anticancer research 2003, 23;4133-4140
- Sehouli J. Möglichkeiten und Grenzen der Diagnostik des Ovarialkarzinoms. Journal Onkologie, 01/2003;4-6
- Sehouli J., Lichtenegger W., Hauptmann S., Dietel M.-Therapie von Borderline-Tumoren des Ovars-Frauenarzt 2002;43;1202-1207
- Sehouli J., Lichtenegger W.-Neue Therapien in der Gynäkologischen Onkologie-Mit den wichtigsten Ergebnissen des 40. Kongresses der

American Society of Clinical Oncology (ASCO); Update 2004/2005
Akademos

- Sehouli J., Mustea A., Koensgen D., Lichtenegger W.-Interleukin-1 Receptor Antagonist Gene Polymorphism in Epitelial Ovarian Cancer-Cancer Epidemiology Biomarkers&Prevention Nov.2003;12;1205-1208
- Sehouli J., Mustea A., Könsgen D., Lichtenegger W.-Etablierte und experimentelle Prognosefaktoren des Ovariakarzinoms.Zentralbl Gynakol 2004;126;315-322
- Sehouli J., Mustea A., Konsgen D. et al.-Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Res 2002; 22: 3421–3424
- Sevela P, Vavra N, Schemper M et al.-Prognostic factors for survival in stage I epithelial ovarian carcinoma.Cancer 1990;65;2349-2352
- Shirodaria S., Smith J. et al.-Polymorphisms in the IL-1 A gene are correlated with levels of inerleukin-1 alpha protein in gingival crevicular fluid of teeth with severe periodontal disease-J Dent Res 2000;79;1864-1869
- Silvenberg SG-Prognostic significance of pathologic features of ovarian carcinoma (Rewiew). Current Topics Pathol 1989;78;85-109
- Smith DR, Kunkel SL, Standiford TJ, et al.-The production of interleukin 1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 1993;143:794-803
- Talerman A.-Ovarian Pathology.-Current Opinion in Obstetrics and Gynecology 1992;4;:608-15
- The ICON and AGO Collaborators.-Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial. The Lancet 2003;361:2099-2106
- Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S.-Age as prognostic factor in ovarian carcinoma. Cancer 1993;71:606-614
- Tingulstad S., Skjeldestad FE et al.-Survival and Prognostic Factors in patients with ovarian cancer-The American College of Obstetricians and Gynecologists 2003 May;101 (5);885-891

- TNM Classification of Malignant Tumours.-4th edition, 2nd revision 1992. Springer Verlag
- Tomimatsu S., Ichikura T., Mochizuki H.-Significant Correlation between Expression of Interleukin-1 α and Liver Metastasis in gastric carcinoma-Cancer 2001 April.;91(7);1272-1276
- Tsuruchi N., Toshiharu K., Tsukamoto N. et al.-Relationship between Paraaortic Lymph Node Involvement and Intraperitoneal Spread in Patients with Ovarian Cancer-A Multivariate Analysis-Gynecologic Oncology 1993; 49;51-55
- van der Burg ME, Lammes FB, Verweij J et al. -The role of CA125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1:301-2
- Van Le L, Haskill S, Jaffe GJ and Fowler WC- Expression of interleukin 1 and interleukin 1 receptor antagonist in endometrial cancer. Gynecol Oncol 1991;42:161-164
- Vergote IB, Borner OP, Abeler VM.-Evaluation of serum CA125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987;157:88-92
- Vergote JB, Borner OP, Abeler VM-Evaluation of serum CA125 levels in the monitoring of ovarian cancer.Am J Obstet Gynecol 1987;157;88-92
- Vergote JB, Kaern J, Abeler V et al.-Analysis of prognostic factors in stage I epithelial ovarian cancer: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993;169:40-52
- Vergote JB, De Brabanter J, Fyles A-Prognostic importance of degree of differentiation and cystic rupture in stage I invasive epithelial ovarian carcinoma.Lancet 2001;357;176-182
- Verschraegen CF., Kudelka AP. et al.-Effects of Interleukin-1 α on Ovarian Carcinoma in Patients with Recurrent Disease-European Journal of Cancer 1996;32A (9);1609-1611
- Verweij PJM, van Houwelingen HC-Time-dependent effects of fixed covariates in Cox Regression-Biometrics 1995 March; 1550-1556

- Voronova E., Shouvai D.S. et al.-IL-1 is required for tumor invasiveness and angiogenesis-*Immunology* 2003, March 4;100 (5);2645-2650
- Watson P., Lynch HT-Extracolonic cancer in hereditary nonpolyposis colorectal cancer-*Cancer* 1993;71;677-685
- Wesche H., Korrher C. et al.-The interleukin-1 receptor accessory protein(IL-1 RAcP) is essential for IL-1 induced activation of IL-1 receptor associated kinase (IRAK) and stress-activated protein kinases.-*J Biol Chem* 1997;272:7727-7731
- Wu ML, Whittemore AS et al.- Personal and environmental characteristics related to epithelial ovarian cancer.-*Am J Epidemiol* 1988;128;1216
- Zeisler H., Tempfer C., Joura EA. et al.-Serum Interleukin-1 in Ovarian Cancer Patients-*European Journal of Cancer* 1998;34(6);931-933
- Zeng Z-R, Hu P-J, et. al.-Association of interleukin 1 β gene polymorphism and gastric cancers in high and low prevalence regions in China-*Gut* 2003;52;1684-1689